- Home
- TRMD vs GPCR Comparison
TRMD vs GPCR Comparison
Compare TRMD & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRMD
- GPCR
- Stock Information
- Founded
- TRMD 1889
- GPCR 2016
- Country
- TRMD United Kingdom
- GPCR United States
- Employees
- TRMD N/A
- GPCR N/A
- Industry
- TRMD Marine Transportation
- GPCR
- Sector
- TRMD Consumer Discretionary
- GPCR
- Exchange
- TRMD Nasdaq
- GPCR Nasdaq
- Market Cap
- TRMD 1.9B
- GPCR 1.6B
- IPO Year
- TRMD N/A
- GPCR 2023
- Fundamental
- Price
- TRMD $18.91
- GPCR $23.77
- Analyst Decision
- TRMD Buy
- GPCR Strong Buy
- Analyst Count
- TRMD 1
- GPCR 7
- Target Price
- TRMD $48.00
- GPCR $81.29
- AVG Volume (30 Days)
- TRMD 948.9K
- GPCR 737.4K
- Earning Date
- TRMD 03-06-2025
- GPCR 03-07-2025
- Dividend Yield
- TRMD 30.93%
- GPCR N/A
- EPS Growth
- TRMD N/A
- GPCR N/A
- EPS
- TRMD 7.70
- GPCR N/A
- Revenue
- TRMD $1,641,593,000.00
- GPCR N/A
- Revenue This Year
- TRMD N/A
- GPCR N/A
- Revenue Next Year
- TRMD N/A
- GPCR N/A
- P/E Ratio
- TRMD $2.55
- GPCR N/A
- Revenue Growth
- TRMD 3.90
- GPCR N/A
- 52 Week Low
- TRMD $17.77
- GPCR $22.33
- 52 Week High
- TRMD $40.47
- GPCR $62.74
- Technical
- Relative Strength Index (RSI)
- TRMD 38.99
- GPCR 37.89
- Support Level
- TRMD $19.11
- GPCR $22.33
- Resistance Level
- TRMD $19.64
- GPCR $25.17
- Average True Range (ATR)
- TRMD 0.63
- GPCR 1.73
- MACD
- TRMD -0.11
- GPCR -0.37
- Stochastic Oscillator
- TRMD 1.27
- GPCR 15.94
About TRMD TORM plc
TORM PLC operates as a shipping company. The company owns and operates product tankers. It is engaged in the transportation of refined oil products The company transports clean petroleum products including gasoline, jet fuel, naphtha, and diesel oil, as well as other clean products. Its segments include the Tanker segment, and Marine Exhaust segment.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.